Ovarian Cancer | Specialty

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

Shifts In Ovarian Cancer Treatment Options Necessitate Continued Research

May 29th 2023

Whitfield B. Growdon, MD, discusses the role PARP inhibitors have played in ovarian cancer since their introduction to the field, the updated clinical trial data that contributed to the indication withdrawals for these agents, and where future research in this area may be headed.

Dr Cohen on Key Trials Supporting the Use of PARP Inhibitors in Ovarian Cancer

May 25th 2023

Joshua G. Cohen, MD, FACOG, FACS, discusses key trials supporting the use of PARP inhibitor maintenance therapy in upfront setting in ovarian cancer.

Hormonal Maintenance Therapy Offers Deescalated Option for Low-Grade Serous Ovarian Cancers

May 12th 2023

Patients with low-grade serous ovarian carcinoma historically have demonstrated a benefit with hormonal maintenance therapy following cytoreductive surgery and platinum-based chemotherapy.

FDA Grants Fast Track Designation to ACR-368 in Platinum-resistant Ovarian Cancer and Endometrial Cancer

May 9th 2023

The FDA has granted fast track designations to ACR-368 monotherapy for the treatment of patients with platinum-resistant ovarian cancer and endometrial cancer who are positive for predicted sensitivity to the agent using Acrivon Therapeutics’ OncoSignature® test.

Interval Cytoreductive Surgery After Chemo Boosts Survival in Stage IV Epithelial Ovarian Cancer

May 8th 2023

Liat Hogen, MD, FRCSC, discussed the potential benefit for cytoreductive surgery in patients with initially unresectable stage IV epithelial ovarian cancer and the implications of findings from this retrospective analysis on future clinical decisions.

ANNIE Data Support Anlotinib/Niraparib Combo as Late-line Option in Platinum-resistant Ovarian Cancer

May 6th 2023

The TKI anlotinib plus the PARP inhibitor niraparib continued to provide overall survival benefit with an acceptable safety profile when given to patients with platinum-resistant recurrent ovarian cancer.

Mirvetuximab Soravtansine Improves PFS, OS in FRα+ Platinum-Resistant Ovarian Cancer

May 3rd 2023

Mirvetuximab soravtansine-gynx led to a clinically meaningful and statistically significant improvement in progression-free survival, overall survival, and objective response rate vs single-agent chemotherapy in patients with platinum-resistant ovarian cancer whose tumors express high levels of folate receptor alpha, according to topline findings from the phase 3 MIRASOL trial.

Dr Crane on PARP Inhibitor Maintenance in Ovarian Cancer

April 28th 2023

Erin K. Crane, MD, MPH, discusses findings from 3 trials demonstrating the benefits of PARP inhibitor maintenance in patients with ovarian cancer.

Dr Han on the Use of HIPEC in Ovarian Cancer

April 27th 2023

Ernest S. Han, MD, PhD, discusses the use of hyperthermic intraperitoneal chemotherapy in ovarian cancer.

B7-H4 Is Validated as a Target for ADCs in High-Grade Serous Ovarian Carcinoma

April 27th 2023

Sarah B. Gitto, PhD, discusses the process of investigating the B7-H4 as a viable target for drug development in treatment-resistant ovarian cancer.

Dr Hathaway on the Investigation of Distress on the TME in Ovarian Cancer

April 25th 2023

Cassandra A. Hathaway, MD, discusses the rationale for investigating the association between distress, such as depression, and the tumor immune microenvironment in patients with ovarian cancer.

Restricted Indication for Maintenance Niraparib Therapy in Recurrent Ovarian Cancer Further Supported by Final Survival Analysis of NOVA Trial

April 25th 2023

Ursula A. Matulonis highlights previous data from the phase 3 ENGOT-OV16/NOVA trial initial readout and subsequent preplanned overall survival analysis, discusses new findings from the final analysis, and emphasizes how these data clarify some of the study’s limitations and reinforce the importance of adhering to the adjusted FDA label for niraparib in recurrent ovarian cancer.

Ribociclib Plus Letrozole Has Activity in Recurrent Low-Grade Serous Ovarian Cancer

April 24th 2023

Brian M. Slomovitz, MD, discusses key efficacy and safety data seen with ribociclib and letrozole in the GOG 3026 trial and planned efforts to identify associated biomarkers and pursue FDA approval for the combination in advanced, recurrent low-grade serous ovarian cancer.

Gushchin and Diaz-Montes Describe QOL Outcomes After Cytoreduction and HIPEC in Ovarian Cancer

April 20th 2023

Drs Gushchin and Diaz-Montes discuss findings from the HOT trial evaluating health-related quality of life outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with primary ovarian cancer.

Dr Alvero on Antitumor Immunological Memory in Ovarian Cancer Models

April 13th 2023

Ayesha Alvero, MD, MSc, discusses findings from a preclinical study investigating the antitumor effects and recurrence prevention abilities of a virus-like vesicle thought to establish immunological memory in mouse models with ovarian cancer.

Neoadjuvant Chemoimmunotherapy Combination Is Active and Tolerable in Ovarian Cancer

April 13th 2023

Jung-Yun Lee, MD, PhD, discusses the TRU-D trial within the context of prior negative trials to emphasize the need for more effective therapies in advanced-stage ovarian cancer, highlights key findings from TRU-D, and elaborates on future steps for this research.

Dr Fashemi on the Effect of Entinostat on Olaparib Responsiveness in Mouse HRP Ovarian Cancer Models

April 12th 2023

Bisiayo Fashemi, PhD, discusses how the addition of entinostat to olaparib could help combat PARP inhibitor-resistance in homologous recombination proficient ovarian cancer, as well as the clinical significance of utilizing mouse organoid models to investigate such strategies.

First-line Senaparib Maintenance Meets PFS End Point in Advanced Ovarian Cancer

April 12th 2023

Maintenance therapy with senaparib improved progression-free survival vs placebo for patients with stage III/IV ovarian carcinoma, fallopian tube cancer, or primary peritoneal cancer who achieved a complete or partial response to first-line platinum-based chemotherapy, meeting the primary end point of the phase 3 FLAMES trial.

MVP-S Plus Low-Dose Cyclophosphamide Elicits Robust Responses in Recurrent Ovarian Cancer

April 10th 2023

Oliver Dorigo, MD, PhD, explains how MVP-S leverages the DPX platform to produce persistent anti-survivin immune infiltration, highlights the antitumor activity and safety observed with the combination when given to patients with recurrent ovarian cancer, and describes additional research efforts underway.

NGS Reveals Molecular Subgroups in Endometrioid Ovarian Carcinoma

April 9th 2023

The use of next-generation sequencing demonstrated that the most prevalent genomic alterations in patients with endometrioid ovarian carcinoma include ARID1A, PIK3CA, PTEN, CTNNB1, KRAS, and P53.